2018 Q1 Form 10-Q Financial Statement
#000156459018010333 Filed on May 02, 2018
Income Statement
| Concept | 2018 Q1 | 2017 Q1 |
|---|---|---|
| Revenue | $15.96M | $6.832M |
| YoY Change | 133.56% | 355.77% |
| Cost Of Revenue | $17.00K | |
| YoY Change | ||
| Gross Profit | $15.94M | |
| YoY Change | ||
| Gross Profit Margin | 99.89% | |
| Selling, General & Admin | $34.90M | $20.30M |
| YoY Change | 71.92% | 26.88% |
| % of Gross Profit | 218.95% | |
| Research & Development | $97.10M | $55.00M |
| YoY Change | 76.55% | 31.23% |
| % of Gross Profit | 609.16% | |
| Depreciation & Amortization | $4.020M | $2.840M |
| YoY Change | 41.55% | 24.56% |
| % of Gross Profit | 25.22% | |
| Operating Expenses | $132.6M | $76.75M |
| YoY Change | 72.76% | 30.34% |
| Operating Profit | -$116.6M | -$69.91M |
| YoY Change | 66.82% | 21.84% |
| Interest Expense | $1.388M | $1.556M |
| YoY Change | -10.8% | -255.6% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $115.0K | -$355.0K |
| YoY Change | -132.39% | -136.94% |
| Pretax Income | -$115.1M | -$68.71M |
| YoY Change | 67.55% | 21.79% |
| Income Tax | $0.00 | |
| % Of Pretax Income | ||
| Net Earnings | -$115.1M | -$68.71M |
| YoY Change | 67.55% | 22.1% |
| Net Earnings / Revenue | -721.48% | -1005.74% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$2.307M | -$1.684M |
| COMMON SHARES | ||
| Basic Shares Outstanding | 40.84M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2018 Q1 | 2017 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $1.122B | $634.1M |
| YoY Change | 76.88% | 14.64% |
| Cash & Equivalents | $470.4M | $216.0M |
| Short-Term Investments | $665.0M | $418.1M |
| Other Short-Term Assets | $42.50M | $3.285M |
| YoY Change | 1193.76% | -58.42% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $6.276M | |
| Other Receivables | ||
| Total Short-Term Assets | $1.164B | $667.3M |
| YoY Change | 74.45% | 18.95% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $204.2M | $181.7M |
| YoY Change | 12.38% | 88.1% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $444.8M | $165.8M |
| YoY Change | 168.28% | -39.44% |
| Other Assets | $24.60M | $24.90M |
| YoY Change | -1.2% | 133.02% |
| Total Long-Term Assets | $702.7M | $405.3M |
| YoY Change | 73.38% | -2.97% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $1.164B | $667.3M |
| Total Long-Term Assets | $702.7M | $405.3M |
| Total Assets | $1.867B | $1.073B |
| YoY Change | 74.04% | 9.59% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $12.00M | $8.800M |
| YoY Change | 36.36% | 180.61% |
| Accrued Expenses | $60.10M | $37.50M |
| YoY Change | 60.27% | 60.94% |
| Deferred Revenue | $45.34M | |
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $1.000M | |
| YoY Change | ||
| Total Short-Term Liabilities | $107.8M | $72.60M |
| YoY Change | 48.48% | 86.31% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $154.5M | $147.6M |
| YoY Change | 4.67% | 98.39% |
| Other Long-Term Liabilities | $34.30M | $37.00M |
| YoY Change | -7.3% | -37.07% |
| Total Long-Term Liabilities | $188.8M | $184.6M |
| YoY Change | 2.28% | 38.59% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $107.8M | $72.60M |
| Total Long-Term Liabilities | $188.8M | $184.6M |
| Total Liabilities | $296.6M | $257.2M |
| YoY Change | 15.32% | 49.36% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$943.2M | |
| YoY Change | ||
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $1.570B | $815.4M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $1.867B | $1.073B |
| YoY Change | 74.04% | 9.59% |
Cashflow Statement
| Concept | 2018 Q1 | 2017 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$115.1M | -$68.71M |
| YoY Change | 67.55% | 22.1% |
| Depreciation, Depletion And Amortization | $4.020M | $2.840M |
| YoY Change | 41.55% | 24.56% |
| Cash From Operating Activities | -$108.8M | -$75.30M |
| YoY Change | 44.52% | 104.79% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $7.452M | $26.02M |
| YoY Change | -71.36% | 568.31% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$257.3M | $21.57M |
| YoY Change | -1292.72% | -68.44% |
| Cash From Investing Activities | -$264.7M | -$4.450M |
| YoY Change | 5848.88% | -106.9% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $48.70M | $3.040M |
| YoY Change | 1501.97% | 375.74% |
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 71.68M | 16.87M |
| YoY Change | 324.88% | 2535.94% |
| NET CHANGE | ||
| Cash From Operating Activities | -108.8M | -75.30M |
| Cash From Investing Activities | -264.7M | -4.450M |
| Cash From Financing Activities | 71.68M | 16.87M |
| Net Change In Cash | -301.9M | -62.88M |
| YoY Change | 380.07% | -322.03% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$108.8M | -$75.30M |
| Capital Expenditures | $7.452M | $26.02M |
| Free Cash Flow | -$116.3M | -$101.3M |
| YoY Change | 14.75% | 149.17% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q1 | blue |
Financing Lease Obligation Noncurrent
FinancingLeaseObligationNoncurrent
|
154545000 | |
| CY2017Q4 | blue |
Financing Lease Obligation Noncurrent
FinancingLeaseObligationNoncurrent
|
154749000 | |
| CY2017Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
76745000 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
|
918900000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
|
704100000 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
|
142700000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
|
134400000 | |
| CY2018Q1 | us-gaap |
Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
|
0 | |
| CY2017Q4 | us-gaap |
Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
|
0 | |
| CY2018Q1 | blue |
License And Royalty Revenue
LicenseAndRoyaltyRevenue
|
349000 | |
| CY2018Q1 | blue |
Cost Of License And Royalty Revenue
CostOfLicenseAndRoyaltyRevenue
|
17000 | |
| CY2018Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
534000 | |
| CY2018Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
132586000 | |
| CY2018Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-116629000 | |
| CY2018Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
1388000 | |
| CY2017Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
1556000 | |
| CY2018Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
115000 | |
| CY2017Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-355000 | |
| CY2018Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-115126000 | |
| CY2017Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-68712000 | |
| CY2018Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-115126000 | |
| CY2017Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-68712000 | |
| CY2018Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.31 | |
| CY2017Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.68 | |
| CY2018Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
49923000 | |
| CY2017Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
40836000 | |
| CY2018Q1 | blue |
Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesArisingDuringPeriodNetOfTax
|
-844000 | |
| CY2017Q1 | blue |
Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesArisingDuringPeriodNetOfTax
|
-101000 | |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-844000 | |
| CY2017Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-101000 | |
| CY2018Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-115970000 | |
| CY2017Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-68813000 | |
| CY2018Q1 | blue |
Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax
|
0 | |
| CY2017Q1 | blue |
Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax
|
0 | |
| CY2018Q1 | blue |
Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
|
534000 | |
| CY2017Q1 | blue |
Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
|
1433000 | |
| CY2018Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
4020000 | |
| CY2017Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
2844000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
22995000 | |
| CY2017Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
11481000 | |
| CY2018Q1 | us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
2403000 | |
| CY2017Q1 | us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
838000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
13486000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
3105000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-737000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-3257000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
4573000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-13318000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-13966000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-3969000 | |
| CY2018Q1 | blue |
Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
|
-32000 | |
| CY2017Q1 | blue |
Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
|
462000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-108822000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-75303000 | |
| CY2018Q1 | blue |
Payments To Acquire Property Plant And Equipment Including Assets Under Financing Lease Obligations
PaymentsToAcquirePropertyPlantAndEquipmentIncludingAssetsUnderFinancingLeaseObligations
|
7452000 | |
| CY2017Q1 | blue |
Payments To Acquire Property Plant And Equipment Including Assets Under Financing Lease Obligations
PaymentsToAcquirePropertyPlantAndEquipmentIncludingAssetsUnderFinancingLeaseObligations
|
26024000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-4454000 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
402413000 | |
| CY2017Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
82940000 | |
| CY2018Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
145140000 | |
| CY2018Q1 | blue |
Proceeds From Public Offering Of Common Stock Net Of Issuance Costs
ProceedsFromPublicOfferingOfCommonStockNetOfIssuanceCosts
|
48701000 | |
| CY2018Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
19984000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-264725000 | |
| CY2017Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
104510000 | |
| CY2018Q1 | blue |
Proceeds From Reimbursement Of Assets Under Financing Lease Obligation
ProceedsFromReimbursementOfAssetsUnderFinancingLeaseObligation
|
3098000 | |
| CY2017Q1 | blue |
Proceeds From Reimbursement Of Assets Under Financing Lease Obligation
ProceedsFromReimbursementOfAssetsUnderFinancingLeaseObligation
|
13831000 | |
| CY2018Q1 | us-gaap |
Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
|
106000 | |
| CY2017Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
3040000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
71677000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
16871000 | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-301870000 | |
| CY2017Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-62886000 | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
772268000 | |
| CY2016Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
293277000 | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
470398000 | |
| CY2017Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
230391000 | |
| CY2018Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
2817000 | |
| CY2017Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
5971000 | |
| CY2017Q1 | blue |
Assets Acquired Under Financing Lease Obligation
AssetsAcquiredUnderFinancingLeaseObligation
|
1269000 | |
| CY2018Q1 | blue |
Tenant Improvements Under Financing Lease Included In Tenant Improvements Receivable
TenantImprovementsUnderFinancingLeaseIncludedInTenantImprovementsReceivable
|
14000 | |
| CY2017Q1 | blue |
Tenant Improvements Under Financing Lease Included In Tenant Improvements Receivable
TenantImprovementsUnderFinancingLeaseIncludedInTenantImprovementsReceivable
|
12687000 | |
| CY2018Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bluebird bio, Inc. (the “Company” or “bluebird”) was incorporated in Delaware on April 16, 1992, and is headquartered in Cambridge, Massachusetts. The Company researches, develops, manufactures and plans to commercialize gene therapies for the treatment of severe genetic diseases and cancer. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide general and administrative support for these operations.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s clinical programs in severe genetic diseases include its LentiGlobin<sup style="font-size:85%; vertical-align:top">®</sup> product candidate to treat transfusion-dependent β-thalassemia, or TDT, and to treat severe sickle cell disease, or severe SCD, and its Lenti-D<sup style="font-size:85%; vertical-align:top">TM</sup> product candidate to treat cerebral adrenoleukodystrophy, or CALD, a rare hereditary neurological disorder. The Company’s programs in oncology are built upon its leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121 and bb21217, which are product candidates in oncology under the Company’s collaboration arrangement with Celgene Corporation (“Celgene”), are CAR T cell product candidates for the treatment of multiple myeloma. Refer to Note 8, “<font style="font-style:italic;">Collaboration revenue</font>” for further discussion of the Company’s collaboration with Celgene.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2018, the Company had cash, cash equivalents and marketable securities of $1.57 billion. Although the Company has incurred recurring losses and expects to continue to incur losses for the foreseeable future, the Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund current operations for at least the next twelve months. </p></div> | |
| CY2018Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:2.27%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the <font style="color:#000000;">reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially</font> from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, among others: subsequent fair value estimates used to assess potential impairment of long-lived assets, including goodwill and intangible assets, financing lease obligation, contingent consideration, stock-based compensation expense, accrued expenses, revenue and income taxes.</p></div> | |
| CY2018Q1 | dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
1992-04-16 | |
| CY2018Q1 | us-gaap |
Investments And Cash
InvestmentsAndCash
|
1570000000 | |
| CY2018Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2018Q1 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
45344000 | |
| CY2018Q1 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
31468000 | |
| CY2018Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-943183000 | |
| CY2018Q1 | us-gaap |
Contract With Customer Timing Of Satisfaction Of Performance Obligation And Payment
ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment
|
Under ASC 605, the Company accounted for contract modifications to the Celgene collaboration as they occurred and the accounting for those changes was prospective in nature. Through the application of the practical expedient discussed above in connection with the adoption of Topic 606, the Company reflected the aggregate effect of all modifications to the Celgene collaboration when identifying the satisfied and unsatisfied performance obligations, determining the transaction price, and allocating the transaction price. As a result, although the performance obligations identified under Topic 606 were generally consistent with the units of account identified under ASC 605, the timing of the allocation of the transaction price to the identified performance obligations under Topic 606 differed from the allocations of consideration under ASC 605. Accordingly, the transaction price ultimately allocated to each performance obligation under Topic 606 differed from the amounts allocated under ASC 605. | |
| CY2018Q1 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
7900000 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
216001000 | |
| CY2018Q1 | blue |
Restricted Cash Included In Receivables And Other Current Assets
RestrictedCashIncludedInReceivablesAndOtherCurrentAssets
|
100000 | |
| CY2017Q1 | blue |
Restricted Cash Included In Receivables And Other Current Assets
RestrictedCashIncludedInReceivablesAndOtherCurrentAssets
|
627000 | |
| CY2018Q1 | blue |
Restricted Cash Included In Restricted Cash And Other Non Current Assets
RestrictedCashIncludedInRestrictedCashAndOtherNonCurrentAssets
|
13763000 | |
| CY2017Q1 | blue |
Restricted Cash Included In Restricted Cash And Other Non Current Assets
RestrictedCashIncludedInRestrictedCashAndOtherNonCurrentAssets
|
13763000 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
1114312000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
859375000 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
1000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
1000 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
4490000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
3579000 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
1109823000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
855797000 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | |
| CY2017Q1 | us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
0 | |
| CY2017Q1 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
0 | |
| CY2018Q1 | blue |
Additional Cash Cash Equivalent And Marketable Securities Related Text
AdditionalCashCashEquivalentAndMarketableSecuritiesRelatedText
|
90 days or less | |
| CY2018Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
223159000 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
215455000 | |
| CY2018Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
18929000 | |
| CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
15849000 | |
| CY2018Q1 | blue |
Accrued Goods And Services
AccruedGoodsAndServices
|
38067000 | |
| CY2017Q4 | blue |
Accrued Goods And Services
AccruedGoodsAndServices
|
29533000 | |
| CY2018Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
10242000 | |
| CY2017Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
19657000 | |
| CY2018Q1 | blue |
Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
|
10173000 | |
| CY2017Q4 | blue |
Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
|
4584000 | |
| CY2018Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1599000 | |
| CY2017Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1402000 | |
| CY2018Q1 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
1048000 | |
| CY2017Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
1051000 | |
| CY2018Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
559000 | |
| CY2017Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
838000 | |
| CY2016Q4 | blue |
Contractual Obligation Agreement Period
ContractualObligationAgreementPeriod
|
P5Y | |
| CY2016Q4 | blue |
Contractual Obligation Agreement Renewal Period
ContractualObligationAgreementRenewalPeriod
|
P3Y | |
| CY2016Q4 | blue |
Contractual Obligation Fees
ContractualObligationFees
|
3000000 | |
| CY2016Q4 | blue |
Contractual Obligation Advance Fees Payment
ContractualObligationAdvanceFeesPayment
|
2000000 | |
| CY2016Q4 | blue |
Contractual Obligation Fees Payable
ContractualObligationFeesPayable
|
1000000 | |
| CY2016Q4 | us-gaap |
Maintenance Costs
MaintenanceCosts
|
9800000 | |
| CY2018Q1 | blue |
Contractual Obligation Termination Description
ContractualObligationTerminationDescription
|
The Company may terminate this agreement with six months’ notice and a one-time termination fee prior to July 1, 2018, or twelve months’ notice and a one-time termination fee thereafter. | |
| CY2018Q1 | blue |
Decrease In Letter Of Credit Related To New Lease Agreement
DecreaseInLetterOfCreditRelatedToNewLeaseAgreement
|
9200000 | |
| CY2018Q1 | us-gaap |
Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
|
12000000 | |
| CY2018Q1 | us-gaap |
Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
|
12000000 | |
| CY2018Q1 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
13966000 | |
| CY2018Q1 | us-gaap |
Contract With Customer Asset Net
ContractWithCustomerAssetNet
|
0 | |
| CY2017Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
4635000 | |
| CY2018Q1 | blue |
Additions To Accounts Receivable Net Current
AdditionsToAccountsReceivableNetCurrent
|
1641000 | |
| CY2018Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
6276000 | |
| CY2017Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
76812000 | |
| CY2018Q1 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
62846000 | |
| CY2017Q4 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
3200000 | |
| CY2017Q4 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
185.00 | |
| CY2017Q4 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
569800000 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
300000 | |
| CY2018Q1 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
185.00 | |
| CY2018Q1 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
48700000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
|
2000000 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
|
1600000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
2000000 | |
| CY2018Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
22995000 | |
| CY2017Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
11481000 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3755000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1009000 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
301000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
17000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4446000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1844000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
4437000 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
67.91 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
203.72 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
65.53 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
107.83 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
98.91 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
52.56 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
98.91 | |
| CY2018Q1 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
19700000 | |
| CY2018Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5372000 | |
| CY2017Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
4640000 |
